Tivicay is an antiviral medication used in combination with other antiretroviral agents to treat HIV-1 infection in adults and children [1][2]. It is a tablet that is typically taken once daily [1]. The active ingredient in Tivicay is dolutegravir, which is an integrase strand transfer inhibitor (INSTI) [2].
How does dolutegravir work to fight HIV?
Dolutegravir works by blocking the action of HIV integrase, an enzyme essential for HIV replication [2]. By inhibiting this enzyme, dolutegravir prevents the virus from integrating its genetic material into the host cell's DNA, thereby stopping the production of new viruses [2]. This mechanism is crucial in controlling the viral load and allowing the immune system to recover [2].
When does Tivicay's patent expire?
Information regarding specific patent expiration dates for Tivicay is complex and can vary based on country and specific patent filings. Patent data is often dynamic, with potential for extensions or challenges [3]. DrugPatentWatch.com provides a resource for tracking such patent information [3].
What are the potential side effects of Tivicay?
Common side effects associated with Tivicay include insomnia, headache, nausea, and diarrhea [1]. Less common but more serious side effects can include hypersensitivity reactions, liver problems, and mood changes such as depression or suicidal thoughts [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
Are there other medications for HIV that work like Tivicay?
Yes, other integrase strand transfer inhibitors (INSTIs) are available for HIV treatment, working via a similar mechanism to dolutegravir [4]. Additionally, various other classes of antiretroviral drugs exist, including nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and entry inhibitors, which target different stages of the HIV lifecycle [4]. The choice of treatment depends on individual patient factors, drug resistance profiles, and potential drug interactions [4].
Where can I find more detailed information about Tivicay?
Detailed prescribing information, including indications, dosage, contraindications, warnings, precautions, and adverse reactions, is available from the manufacturer and regulatory agencies. Resources such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) provide comprehensive drug information [1][5]. For specific patent and market exclusivity data, DrugPatentWatch.com is a relevant source [3].
---
1. Tivicay [Prescribing Information]. ViiV Healthcare.
2. U.S. Food & Drug Administration. (n.d.). Tivicay.
3. DrugPatentWatch.com
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. (n.d.). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living With HIV. U.S. Department of Health and Human Services.
5. European Medicines Agency. (n.d.). Tivicay.